TY - JOUR
T1 - Effects of irradiation and cisplatin on human glioma spheroids: Inhibition of cell proliferation and cell migration
AU - Fehlauer, Fabian
AU - Muench, Martina
AU - Rades, Dirk
AU - Stalpers, Lukas J.A.
AU - Leenstra, Sieger
AU - Van Der Valk, Paul
AU - Slotman, Ben
AU - Smid, Ernst J.
AU - Sminia, Peter
N1 - Funding Information:
Acknowledgments The authors acknowledge Dr. R. Bjerkvig (Department of Anatomy and Cell Biology, University of Bergen, Norway) for his hospitality during the laboratory visit of Dr. F. Fehlauer in Bergen and his critical comments on the manuscript. We also wish to thank the members of the European Cancer Centre (ECC) Neuro-Oncology Group for their collaborations, insightful discussions and encouragement. Dr. F. Fehlauer was research fellow and supported by a grand of the Deutsche Forschungsgeme-inschaft (Bonn, Germany) and the ECC (Amsterdam, The Netherlands). Furthermore, we thank Dr. Dr. A.J. Terzis (Department of Neurosurgery, University of Luebeck, Germany) for providing the GaMg cell line.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/11
Y1 - 2005/11
N2 - Purpose: Investigation of cell migration and proliferation of human glioma cell line spheroids (CLS) and evaluation of morphology, apoptosis, and immunohistochemical expression of MIB-1, p53, and p21 of organotypic muticellular spheroids (OMS) following cisplatin (CDDP) and irradiation (RT). Material and methods: Spheroids of the GaMg glioma cell line and OMS prepared from biopsy tissue of six glioblastoma patients were used. Radiochemosensitvity (5 μg/ml CDDP followed by RT) was determined using migration and proliferation assays on CLS. In OMS, histology and immunohistochemical studies of MIB-1, p53, and p21 expression were examined 24 and 48 h following treatment. Results: Combination treatment led to a migration inhibition of 38% (CDDP 13%; RT 27%) and specific growth delay of 2.6 (CDDP 1.3; RT 2.1) in CLS. Cell cycle analysis after combination treatment showed an accumulation of cells in the G2/M phase. In OMS, apoptosis increased, cell proliferation decreased, and p53/p21 expression increased more pronounced following CDDP+RT. No morphological damage was observed. Conclusion: CDDP can lead to enhancement of the RT effect in spheroids of both human glioma cell line spheroids and biopsy spheroids from glioblastoma specimens. The exerted effect is additive rather than synergistic.
AB - Purpose: Investigation of cell migration and proliferation of human glioma cell line spheroids (CLS) and evaluation of morphology, apoptosis, and immunohistochemical expression of MIB-1, p53, and p21 of organotypic muticellular spheroids (OMS) following cisplatin (CDDP) and irradiation (RT). Material and methods: Spheroids of the GaMg glioma cell line and OMS prepared from biopsy tissue of six glioblastoma patients were used. Radiochemosensitvity (5 μg/ml CDDP followed by RT) was determined using migration and proliferation assays on CLS. In OMS, histology and immunohistochemical studies of MIB-1, p53, and p21 expression were examined 24 and 48 h following treatment. Results: Combination treatment led to a migration inhibition of 38% (CDDP 13%; RT 27%) and specific growth delay of 2.6 (CDDP 1.3; RT 2.1) in CLS. Cell cycle analysis after combination treatment showed an accumulation of cells in the G2/M phase. In OMS, apoptosis increased, cell proliferation decreased, and p53/p21 expression increased more pronounced following CDDP+RT. No morphological damage was observed. Conclusion: CDDP can lead to enhancement of the RT effect in spheroids of both human glioma cell line spheroids and biopsy spheroids from glioblastoma specimens. The exerted effect is additive rather than synergistic.
UR - http://www.scopus.com/inward/record.url?scp=27644577735&partnerID=8YFLogxK
U2 - 10.1007/s00432-005-0014-3
DO - 10.1007/s00432-005-0014-3
M3 - Journal articles
C2 - 16096850
AN - SCOPUS:27644577735
SN - 0171-5216
VL - 131
SP - 723
EP - 732
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 11
ER -
